Pfizer Reshapes Portfolio With New Partnerships Oncology Push And Pricing Shifts [Yahoo! Finance]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance
Pfizer (NYSE:PFE) licensed Novavax's Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and bezuclastinib in gastrointestinal cancer. Pfizer agreed to provide significant drug discounts under the U.S. government's TrumpRx initiative. Management is refocusing R&D and capital toward oncology and obesity through targeted investments and acquisitions. For investors watching NYSE:PFE, these moves come as the stock trades around $26.44, with a value score of 5 and a mixed return profile over recent years. One year, three year, and five year returns of 6.9%, 28.1% decline, and 2.8% decline sit alongside shorter term gains of 3.1% over 7 days, 6.2% over 30 days, and 5.0% year to date. Pfizer's push into oncology, obesity, and vaccine technology, combined with drug pricing agreements, could influence where future capital and management attention go inside the business. As these ini
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story [Yahoo! Finance]Yahoo! Finance
- Pfizer Reshapes Portfolio With Obesity Bet, Vaccine Deal And Pricing Shift [Yahoo! Finance]Yahoo! Finance
- BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets [Yahoo! Finance]Yahoo! Finance
- Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today? [Seeking Alpha]Seeking Alpha
- Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline [Yahoo! Finance]Yahoo! Finance
NVAX
Earnings
- 11/6/25 - Miss
NVAX
Sec Filings
- 1/26/26 - Form 4
- 1/20/26 - Form 8-K
- 1/12/26 - Form 8-K
- NVAX's page on the SEC website